<div id="readability-page-1"><article><div>, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York.<img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.jpg"/><ul type="disc"><li>2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link here</li></ul>The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the fireside chat will be available for 30 days.If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective representative.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.ContactsFor Investors:Vivian Wu 628-895-0661 VWu@nektar.comCorey Davis, Ph.D. LifeSci Advisors 212-915-2577 cdavis@lifesciadvisors.com For Media:Susan Roberts LifeSci Communications 202-779-0929 sroberts@lifescicomms.com SOURCE Nektar Therapeutics</div></article></div>

NKTR

Nektar Therapeutics (Nasdaq: NKTR) will webcast its participation in the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026. The fireside chat is scheduled for June 3 at 1:20 p.m. ET, with a replay available for 30 days. Nektar focuses on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG).

StockTitan

Nektar Therap

VG Health

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares US Pharma

Ark Genomic Revolution ETF

SPDR S&P Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Health Care Select Sector SPDR

Jefferies Financial

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York | NKTR Stock News